Melanie C. Ruzek

Melanie C. Ruzek

Auto-generated profile, based on publicly available information

Melanie C. Ruzek

AbbVie Bioresearch Center, 100 Research Drive, Worcester, MA 01605, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 March 2024 in Science Translational Medicine
Verified
Journal Article
Closed access
MMMichael J. McPherson
Michael J. McPherson
AHAdrian D. Hobson
Adrian D. Hobson
AHAxel Hernandez
Axel Hernandez
CMChristopher C. Marvin
Christopher C. Marvin
WWWendy Waegell
Wendy Waegell
RSRobert Stoffel
Robert Stoffel
Glucocorticoids (GCs) are efficacious drugs used for treating many inflammatory diseases, but the dose and duration of administration are limited because of severe side effects. We therefore sought to identify an approach to selectively target GCs to inflamed tissue. Previous work identified that anti–tumor necrosis factor (TNF) antibodies that bind to transmembrane TNF undergo internalization; therefore, an anti-TNF antibody-drug conjugate (ADC) would be mechanistically similar, where lysosomal catabolism could release a GC receptor modulator (GRM) payload to dampen immune cell activity. Consequently, we have generated an anti–TNF-GRM ADC with the aim of inhibiting pro-inflammatory cytokine production from stimulated human immune cells. In an acute mouse model of contact hypersensitivity, a murine surrogate anti–TNF-GRM ADC inhibited inflammatory responses with minimal effect on systemic GC biomarkers. In addition, in a mouse model of collagen-induced arthritis, single-dose administration of the ADC, delivered at disease onset, was able to completely inhibit arthritis for greater than 30 days, whereas an anti-TNF monoclonal antibody only partially inhibited disease. ADC treatment at the peak of disease was also able to attenuate the arthritic phenotype. Clinical data for a human anti–TNF-GRM ADC (ABBV-3373) from a single ascending dose phase 1 study in healthy volunteers demonstrated antibody-like pharmacokinetic profiles and a lack of impact on serum cortisol concentrations at predicted therapeutic doses. These data suggest that an anti–TNF-GRM ADC may provide improved efficacy beyond anti-TNF alone in immune mediated diseases while minimizing systemic side effects associated with standard GC treatment.

21 October 2022 in Arthritis & Rheumatology
Verified
Journal Article
Closed access
JWJing Wang
Jing Wang
DCDonna Conlon
Donna Conlon
FRFelice Rivellese
Felice Rivellese
ANAlessandra Nerviani
Alessandra Nerviani
MLMyles J. Lewis
Myles J. Lewis
MRMelanie C. Ruzek
Melanie C. Ruzek

1 November 2021 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
YCYonghao Cao
Yonghao Cao
BHBohdan P. Harvey
Bohdan P. Harvey
FHFeng Hong
Feng Hong
MRMelanie Ruzek
Melanie Ruzek
JWJing Wang
Jing Wang
ZKZehra Kaymakcalan
Zehra Kaymakcalan

1 March 2018 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Open access
MRMelanie C. Ruzek
Melanie C. Ruzek
LHLili Huang
Lili Huang
TZTing- Ting Zhang
Ting- Ting Zhang
SBShaughn Bryant
Shaughn Bryant
PSPeter F. Slivka
Peter F. Slivka
GBGuenter Blaich
Guenter Blaich
Despite the efficacy of biologics for treatment of rheumatoid arthritis (RA), many patients show inadequate responses and likely require neutralization of multiple mediators. Neutralization of both interleukin (IL)-1β and IL-17A with monoclonal antibodies showed greater efficacy than either agent alone in a mouse arthritis model with cooperative inhibition of key inflammatory factors, IL-6, granulocyte colony stimulating factor (G-CSF) and CXC chemokine ligand (CXCL)1. Given the potential clinical benefit in RA, we generated a human dual variable domain antibody (DVD-Ig), ABBV-615, capable of simultaneous binding and neutralization of IL-1β and IL-17A. ABBV-615 was characterized and evaluated in cynomolgus monkeys for pharmacokinetics and toxicity to enable clinical development. ABBV-615 exhibited affinities (KD) of 12 and 3 pM on human IL-1β and IL-17A, respectively, and potencies (IC50) of 3 and 58 pM, respectively, as well as excellent drug-like properties. ABBV-615 pharmacokinetics in cynomolgus monkeys was dose proportional from 20 to 100 mg/kg with a mean half-life of 16d. However, a 13-week repeat-dose toxicity study in cynomolgus monkeys revealed time-dependent spontaneous infections exclusively in skin at all doses tested and not historically seen with single agent anti-IL-1α/β or anti-IL-17A. Consistent with reduced resistance to skin infections, IL-1β and IL-17A-stimulated human keratinocytes demonstrate cooperative or compensatory production of key anti-bacterial and inflammatory mediators such as Lipocalin-2 (LCN2), G-CSF, CXCL1, IL-8, tumor necrosis factor (TNF) and IL-6, which aid in defense against skin bacterial infections. These results illustrate the skin-specific antimicrobial mechanisms of IL-1β and IL-17A and highlight the importance of understanding unique combinatorial effects of biological agents.

8 December 2020 in Cytometry Part B: Clinical Cytometry
Verified
Journal Article
Open access
PDF file
TNTeresa Ng
Teresa Ng
PDPatrick K. Dorr
Patrick K. Dorr
PKPreethi Krishnan
Preethi Krishnan
DCDaniel E. Cohen
Daniel E. Cohen
SRSusan Rhee
Susan Rhee
WKWarren M. Kati
Warren M. Kati
With the morbidity and mortality associated with the COVID‐19 pandemic that we are witnessing this year, the risks posed by emerging viral diseases to global health are all too obvious. This pandemic highlights the importance of antiviral drug discovery, which targets emerging viral pathogens, as well as existing pathogenic viruses that undergo continuous evolution. Drug discovery and development is a long and resource intensive process; however, the use of biomarkers can accelerate clinical development of antivirals by providing information regarding diagnosis of specific viral infections, status of infection, potential safety parameters, and antiviral responses. In clinical practice, many of the biomarkers initially utilized to support clinical development are also used for patient care. While viral load is a standard and essential biomarker used to detect the desired viral suppression induced by an antiviral agent, it has become apparent that additional biomarkers, whether related to the virus, the host or as a consequence of the drug's mechanistic effects, are also important for monitoring clinical outcomes associated with an antiviral therapy. This review summarizes the biomarkers used in the clinical development (as well as in clinical practice, where appropriate) of antiviral therapies for hepatitis C virus, hepatitis B virus, human immunodeficiency virus, and severe acute respiratory syndrome coronavirus 2.